Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity?

D’Amico, Ferdinando; Chateau, Thomas; Laurent, V.; Danese, Silvio; Peyrin–Biroulet, Laurent

doi:10.3390/jcm9061691

Cited by 13 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is estimated that the patient should take approximately 1800-2000 mL orally. MR enterography complements endoscopic examination in the analysis of ulcerations, structures and edema [99].…”

Section: Magnetic Resonance Enterographymentioning

confidence: 99%

Crohn’s Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review

Pasternak,

Chrzanowski,

Aebisher

et al. 2023

Life

View full text Add to dashboard Cite

Crohn’s disease is a chronic inflammatory bowel disease that affects the ileum and/or large intestine. At the same time, it can also affect any other part of the human body, i.e., from the mouth to the anus. In Crohn’s disease, the physiology and functioning of the epithelial barrier are inhibited due to the correlation of various factors, such as the environment, genetic susceptibility or intestinal microbiota. The symptoms are very troublesome and cause a significant reduction in quality of life, sometimes occurring with paralyzing permanent damage to the digestive tract, requiring enteral or parenteral nutrition throughout life. In order to make a proper and accurate diagnosis, an appropriately selected diagnostic path in a given clinical entity is necessary. Standard diagnostic methods are: laboratory examination, histopathological examination, endoscopic examination, X-ray, computed tomography, ultrasound examination and magnetic resonance imaging. Medical biology and the analysis of metalloproteinases have also proved helpful in diagnosing changes occurring as a result of Crohn’s disease. Here we provide a thorough review of the latest reports on Crohn’s disease and its genetic conditions, symptoms, morphology, diagnosis (including the analysis of Crohn’s disease biomarkers, i.e., metalloproteinases) and treatment.

show abstract

Section: Magnetic Resonance Enterographymentioning

confidence: 99%

Crohn’s Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review

Pasternak,

Chrzanowski,

Aebisher

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

“…Multiple CD activity scores based on MR Enterography have been proposed to stage the severity of the disease [14], such as the Magnetic Resonance Index of Activity (MaRIA), which is one of the most widely used [15], and the Magnetic Resonance Enterography Global Score (MEGS) [16]. Additional scores also include DWI, such as the Nancy and Clermont scores [11,12].…”

Section: Multiparametric Mri Evaluation Of Bowel Inflammationmentioning

confidence: 99%

Magnetic Resonance Imaging of the Gastrointestinal Tract: Current Role, Recent Advancements and Future Prospectives

et al. 2023

View full text Add to dashboard Cite

This review focuses on the role of magnetic resonance imaging (MRI) in the evaluation of the gastrointestinal tract (GI MRI), analyzing the major technical advances achieved in this field, such as diffusion-weighted imaging, molecular imaging, motility studies, and artificial intelligence. Today, MRI performed with the more advanced imaging techniques allows accurate assessment of many bowel diseases, particularly inflammatory bowel disease and rectal cancer; in most of these diseases, MRI is invaluable for diagnosis, staging, and disease monitoring under treatment. Several MRI parameters are currently considered activity biomarkers for inflammation and neoplastic disease. Furthermore, in younger patients with acute or chronic GI disease, MRI can be safely used for short-term follow-up studies in many critical clinical situations because it is radiation-free. MRI assessment of functional gastro-esophageal and small bowel disorders is still in its infancy but very promising, while it is well established and widely used for dynamic assessment of anorectal and pelvic floor dysfunction; MRI motility biomarkers have also been described. There are still some limitations to GI MRI related to high cost and limited accessibility. However, technical advances are expected, such as faster sequences, more specific intestinal contrast agents, AI analysis of MRI data, and possibly increased accessibility to GI MRI studies. Clinical interest in the evaluation of bowel disease using MRI is already very high, but is expected to increase significantly in the coming years.

show abstract

“…Disease activity in IBD patients is evaluated by combining multiple invasive and/or non-invasive procedures such as patient-reported symptoms, inflammatory markers score, endoscopic assessment, capsule endoscopy, single-or double-balloon enteroscopy, MRI scores, and histology scores [8,[14][15][16][17][18][19][20][21][22]. Endoscopic assessment of the gastrointestinal tract is known to be the gold standard method for assessing disease activity, and it has a good correlation with serological markers; however, because endoscopic assessment is an invasive method, it cannot be performed routinely to monitor disease severity [23][24][25][26][27][28][29][30][31].…”

Section: Disease Classification Activity and Severity Assessment Toolsmentioning

confidence: 99%

Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response

Elhag

Kumar

Saadaoui

et al. 2022

IJMS

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammation of the gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and remitting clinical course that necessitates lifelong monitoring and treatment. Although the availability of a variety of effective therapeutic options including immunomodulators and biologics (such as TNF, CAM inhibitors) has led to a paradigm shift in the treatment outcomes and clinical management of IBD patients, some patients still either fail to respond or lose their responsiveness to therapy over time. Therefore, according to the recent Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) recommendations, continuous disease monitoring from symptomatic relief to endoscopic healing along with short- and long-term therapeutic responses are critical for providing IBD patients with a tailored therapy algorithm. Moreover, considering the high unmet need for novel therapeutic approaches for IBD patients, various new modulators of cytokine signaling events (for example, JAK/TYK inhibitors), inhibitors of cytokines (for example IL-12/IL-23, IL-22, IL-36, and IL-6 inhibitors), anti-adhesion and migration strategies (for example, β7 integrin, sphingosine 1-phosphate receptors, and stem cells), as well as microbial-based therapeutics to decolonize the bed buds (for example, fecal microbiota transplantation and bacterial inhibitors) are currently being evaluated in different phases of controlled clinical trials. This review aims to offer a comprehensive overview of available treatment options and emerging therapeutic approaches for IBD patients. Furthermore, predictive biomarkers for monitoring the therapeutic response to different IBD therapies are also discussed.

show abstract

Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity?

Cited by 13 publications

References 51 publications

Crohn’s Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review

Crohn’s Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review

Magnetic Resonance Imaging of the Gastrointestinal Tract: Current Role, Recent Advancements and Future Prospectives

Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response

Contact Info

Product

Resources

About